Chandipura Virus (CHPV) Antigens & Antibodies

Research-grade reagents for Chandipura virus (CHPV) research — a negative-sense, single-stranded RNA virus belonging to the genus Vesiculovirus within the family Rhabdoviridae. First isolated in 1965 from sand flies in the Chandipura region of India, CHPV remains endemic to South Asia and Central Africa, causing acute encephalitis outbreaks with 40–70% mortality in pediatric populations. Our portfolio includes polyclonal antibodies against all four major structural proteins (G, M, N, P), His-tagged and Fc-tagged recombinant antigens for viral entry mechanism studies, and comprehensive applications for ELISA, Western blot, and immunohistochemistry. CHPV's glycoprotein (G) mediates viral attachment and cell entry; matrix protein (M) organizes virion architecture; nucleoprotein (N) encapsidates viral RNA; and phosphoprotein (P) is essential for RNA-dependent RNA polymerase activity. Validated immunological tools targeting these structural proteins are critical for understanding infection mechanisms, immune responses, and vaccine development. RUO

Why Researchers Choose abinScience

Polyclonal Antibodies (4) Broad epitope recognition targeting all major CHPV structural proteins: glycoprotein (G), matrix protein (M), nucleoprotein (N), and phosphoprotein (P). Validated for Western blot, ELISA, and immunohistochemistry with high specificity and sensitivity for detecting viral antigens in infected cells and tissues.

Recombinant Proteins (6) His-tagged and Fc-tagged recombinant CHPV antigens covering glycoprotein (G), phosphoprotein (P), matrix protein (M), and nucleoprotein (N). Suitable as immunogens, assay standards, positive controls, and coating antigens for ELISA-based serology and neutralization studies.

Viral Glycoprotein (G) Variants CHPV G protein, the primary viral attachment and entry protein, available in three recombinant formats: C-terminal His-tagged, N-terminal His-tagged, and Fc-fusion protein. Essential for cell entry mechanism studies, neutralizing antibody screening, and vaccine development targeting receptor-binding epitopes.

All products manufactured by AtaGenix Laboratories under ISO 9001 & ISO 13485 quality systems.

References

1. Yadav R, Rathod D, Petkar O, et al. Chandipura virus encephalitis: emerging threat to public health in India. Emerg Infect Dis. 2023;29(7):1456-1463. DOI

2. Rao BL, Basu A, Wairagkar NS, et al. A large outbreak of acute encephalitis with high fatality rate in children in Andhra Pradesh, India, in 2003, associated with Chandipura virus infection. Lancet. 2004;364(9437):869-874. DOI

3. Saeed MF, Wang H, Nunes MR, et al. Molecular characterization of Chandipura virus isolates from India. J Gen Virol. 2000;81(Pt 1):49-58. DOI

4. Chadha MS, Comer JA, Lowe L, et al. Chandipura virus epidemic in the Indian subcontinent. Lancet. 2005;365(9462):904-905. DOI